{
    "2019-08-22": [
        [
            {
                "time": "",
                "original_text": "天坛生物(600161.SH)半年度净利润升22.21%至2.94亿元",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "半年度",
                        "净利润",
                        "上升",
                        "22.21%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "天坛生物(600161.SH)：“人凝血酶原复合物”完成临床试验",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "人凝血酶原复合物",
                        "临床试验",
                        "完成"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "天坛生物：上半年净利润同比增22.21%",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "上半年",
                        "净利润",
                        "同比增长",
                        "22.21%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}